• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性阻塞性肺疾病急性加重期流感嗜血杆菌或卡他莫拉菌的痰标本阳性:与稳定期早期阳性结果的相关性评估。

Sputum sample positivity for Haemophilus influenzae or Moraxella catarrhalis in acute exacerbations of chronic obstructive pulmonary disease: evaluation of association with positivity at earlier stable disease timepoints.

机构信息

GSK, Siena, Italy.

ICON, Chennai, India c/o GSK, Wavre, Belgium.

出版信息

Respir Res. 2021 Feb 24;22(1):67. doi: 10.1186/s12931-021-01653-8.

DOI:10.1186/s12931-021-01653-8
PMID:33627095
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7903661/
Abstract

BACKGROUND

Infection with Haemophilus influenzae (Hi) or Moraxella catarrhalis (Mcat) is a risk factor for exacerbation in chronic obstructive pulmonary disease (COPD). The ability to predict Hi- or Mcat-associated exacerbations may be useful for interventions developed to reduce exacerbation frequency.

METHODS

In a COPD observational study, sputum samples were collected at monthly stable-state visits and at exacerbation during two years of follow-up. Bacterial species (Hi, Mcat) were identified by culture and quantitative PCR assay. Post-hoc analyses were conducted to assess: (1) first Hi- or Mcat-positive exacerbations given presence or absence of Hi or Mcat at the screening visit (stable-state timepoint); (2) first Hi- or Mcat-positive exacerbations given presence or absence of Hi or Mcat at stable timepoints within previous 90 days; (3) second Hi- or Mcat-positive exacerbations given presence or absence of Hi or Mcat at stable timepoints within previous 90 days. Percentages and risk ratios (RRs) with 95% confidence intervals were calculated.

RESULTS

PCR results for analyses 1, 2 and 3 (samples from 84, 88 and 83 subjects, respectively) showed that the risk of an Hi- or Mcat-positive exacerbation is significantly higher if sputum sample was Hi- or Mcat-positive than if Hi- or Mcat-negative at previous stable timepoints (apart from Mcat in analysis 3); RRs ranged from 2.1 to 3.2 for Hi and 1.9 to 2.6 for Mcat.For all analyses, the percentage of Hi- or Mcat-positive exacerbations given previous Hi- or Mcat-positive stable timepoints was higher than the percentage of Hi- or Mcat-positive exacerbations if Hi- or Mcat-negative at previous stable timepoints. Percentage of Hi- or Mcat-positive exacerbations given previous Hi- or Mcat-negative stable timepoints was 26.3%-37.0% for Hi and 17.6%-19.7% for Mcat.

CONCLUSIONS

Presence of Hi or Mcat at a stable timepoint was associated with a higher risk of a subsequent Hi- or Mcat-associated exacerbation compared with earlier absence. However, a large percentage of Hi- or Mcat-associated exacerbations was not associated with Hi/Mcat detection at an earlier timepoint. This suggests that administration of an intervention to reduce these exacerbations should be independent of bacterial presence at baseline. Trial Registration https://clinicaltrials.gov/ ; NCT01360398, registered May 25, 2011.

摘要

背景

流感嗜血杆菌(Hi)或卡他莫拉菌(Mcat)感染是慢性阻塞性肺疾病(COPD)恶化的危险因素。预测 Hi 或 Mcat 相关恶化的能力可能有助于开发减少恶化频率的干预措施。

方法

在 COPD 观察性研究中,每月在稳定状态就诊时采集痰标本,并在两年的随访期间采集恶化时的标本。通过培养和定量 PCR 检测鉴定细菌种类(Hi、Mcat)。进行了事后分析以评估:(1)在筛选就诊(稳定状态时间点)时存在或不存在 Hi 或 Mcat 的情况下,首次出现 Hi 或 Mcat 阳性恶化;(2)在之前 90 天内的稳定时间点存在或不存在 Hi 或 Mcat 的情况下,首次出现 Hi 或 Mcat 阳性恶化;(3)在之前 90 天内的稳定时间点存在或不存在 Hi 或 Mcat 的情况下,第二次出现 Hi 或 Mcat 阳性恶化。计算了百分比和风险比(RR)及其 95%置信区间。

结果

分析 1、2 和 3 的 PCR 结果(分别来自 84、88 和 83 名受试者的样本)表明,如果痰样本为 Hi 或 Mcat 阳性,则 Hi 或 Mcat 阳性恶化的风险显著高于之前稳定时间点为 Hi 或 Mcat 阴性的情况(除了分析 3 中的 Mcat);RR 范围为 Hi 为 2.1 至 3.2,Mcat 为 1.9 至 2.6。对于所有分析,与之前稳定时间点为 Hi 或 Mcat 阴性的情况下相比,之前 Hi 或 Mcat 阳性稳定时间点的 Hi 或 Mcat 阳性恶化的百分比更高。之前 Hi 或 Mcat 阴性稳定时间点的 Hi 或 Mcat 阳性恶化的百分比为 Hi 为 26.3%-37.0%,Mcat 为 17.6%-19.7%。

结论

与之前不存在相比,稳定时间点存在 Hi 或 Mcat 与随后的 Hi 或 Mcat 相关恶化的风险更高。然而,很大一部分 Hi 或 Mcat 相关恶化与更早时间点的 Hi/Mcat 检测无关。这表明,为减少这些恶化而给予干预措施不应依赖于基线时的细菌存在。

试验注册

https://clinicaltrials.gov/;NCT01360398,于 2011 年 5 月 25 日注册。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a47a/7903661/9ee7c9f25e5e/12931_2021_1653_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a47a/7903661/3eb3a0e22e98/12931_2021_1653_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a47a/7903661/1cbe99fa4621/12931_2021_1653_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a47a/7903661/1bdbe0ead9b1/12931_2021_1653_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a47a/7903661/9ee7c9f25e5e/12931_2021_1653_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a47a/7903661/3eb3a0e22e98/12931_2021_1653_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a47a/7903661/1cbe99fa4621/12931_2021_1653_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a47a/7903661/1bdbe0ead9b1/12931_2021_1653_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a47a/7903661/9ee7c9f25e5e/12931_2021_1653_Fig4_HTML.jpg

相似文献

1
Sputum sample positivity for Haemophilus influenzae or Moraxella catarrhalis in acute exacerbations of chronic obstructive pulmonary disease: evaluation of association with positivity at earlier stable disease timepoints.慢性阻塞性肺疾病急性加重期流感嗜血杆菌或卡他莫拉菌的痰标本阳性:与稳定期早期阳性结果的相关性评估。
Respir Res. 2021 Feb 24;22(1):67. doi: 10.1186/s12931-021-01653-8.
2
Ex-vivo RNA expression analysis of vaccine candidate genes in COPD sputum samples.在 COPD 痰样本中对候选疫苗基因进行离体 RNA 表达分析。
Respir Res. 2023 Oct 5;24(1):243. doi: 10.1186/s12931-023-02525-z.
3
Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial.用于预防慢性阻塞性肺疾病急性加重的非分型流感嗜血杆菌-卡他莫拉菌疫苗:一项多中心、随机、安慰剂对照、观察者盲法、概念验证的2b期试验。
Lancet Respir Med. 2022 May;10(5):435-446. doi: 10.1016/S2213-2600(21)00502-6. Epub 2022 Jan 10.
4
Impact of bacterial strain acquisition in the lung of patients with COPD: the AERIS study.慢性阻塞性肺疾病患者肺部细菌菌株获得情况的影响:AERIS研究
Infect Dis (Lond). 2022 Nov;54(11):784-793. doi: 10.1080/23744235.2022.2092648. Epub 2022 Jul 6.
5
Sputum strains exhibit diversity within and between COPD subjects.痰液菌株在慢性阻塞性肺疾病(COPD)患者体内及患者之间均表现出多样性。
Int J Chron Obstruct Pulmon Dis. 2018 Nov 8;13:3663-3667. doi: 10.2147/COPD.S180961. eCollection 2018.
6
A detailed analysis of possible efficacy signals of NTHi-Mcat vaccine against severe COPD exacerbations in a previously reported randomised phase 2b trial.对先前报道的一项随机 2b 期临床试验中 NTHi-Mcat 疫苗预防严重 COPD 加重的可能疗效信号进行详细分析。
Vaccine. 2022 Sep 29;40(41):5924-5932. doi: 10.1016/j.vaccine.2022.08.053. Epub 2022 Sep 6.
7
Lower Airway Bacterial Colonization Patterns and Species-Specific Interactions in Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病下呼吸道细菌定植模式和种间特异性相互作用。
J Clin Microbiol. 2018 Sep 25;56(10). doi: 10.1128/JCM.00330-18. Print 2018 Oct.
8
New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.新型细菌菌株与慢性阻塞性肺疾病的急性加重
N Engl J Med. 2002 Aug 15;347(7):465-71. doi: 10.1056/NEJMoa012561.
9
Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study.根据两种不同方案接种三剂非致病性流感嗜血杆菌-卡他莫拉菌(NTHi-Mcat)疫苗的安全性和免疫原性:一项 2 期、随机、观察者盲法研究。
Respir Res. 2022 May 4;23(1):114. doi: 10.1186/s12931-022-02019-4.
10
A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD.一项关于慢性阻塞性肺疾病(COPD)急性加重病因中气道病原体季节动态变化的前瞻性观察队列研究。
Thorax. 2017 Oct;72(10):919-927. doi: 10.1136/thoraxjnl-2016-209023. Epub 2017 Apr 21.

引用本文的文献

1
Cytokine Biomarkers of Exacerbations in Sputum From Patients With Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study.慢性阻塞性肺疾病患者痰液中细胞因子生物标志物与加重的相关性:一项前瞻性队列研究。
J Infect Dis. 2024 Nov 15;230(5):e1112-e1120. doi: 10.1093/infdis/jiae232.
2
Exploring the Role of Gut-Lung Interactions in COPD Pathogenesis: A Comprehensive Review on Microbiota Characteristics and Inflammation Modulation.探讨肠道-肺相互作用在慢性阻塞性肺疾病发病机制中的作用:关于微生物群特征和炎症调节的综合综述
Chronic Obstr Pulm Dis. 2024 May 29;11(3):311-325. doi: 10.15326/jcopdf.2023.0442.
3
Ex-vivo RNA expression analysis of vaccine candidate genes in COPD sputum samples.

本文引用的文献

1
Recent Advances in the Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病急性加重的管理新进展。
Med Clin North Am. 2020 Jul;104(4):615-630. doi: 10.1016/j.mcna.2020.02.003.
2
Potential clinical utility of multiple target quantitative polymerase chain reaction (qPCR) array to detect microbial pathogens in patients with chronic obstructive pulmonary disease (COPD).多重靶标定量聚合酶链反应(qPCR)芯片检测慢性阻塞性肺疾病(COPD)患者微生物病原体的潜在临床应用价值
J Thorac Dis. 2019 Oct;11(Suppl 17):S2254-S2265. doi: 10.21037/jtd.2019.10.39.
3
Bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis.
在 COPD 痰样本中对候选疫苗基因进行离体 RNA 表达分析。
Respir Res. 2023 Oct 5;24(1):243. doi: 10.1186/s12931-023-02525-z.
4
Real-time PCR has advantages over culture-based methods in identifying major airway bacterial pathogens in chronic obstructive pulmonary disease: Results from three clinical studies in Europe and North America.在慢性阻塞性肺疾病中,实时荧光定量聚合酶链反应(Real-time PCR)在鉴定主要气道细菌病原体方面优于基于培养的方法:欧洲和北美的三项临床研究结果
Front Microbiol. 2023 Feb 24;13:1098133. doi: 10.3389/fmicb.2022.1098133. eCollection 2022.
5
Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study.根据两种不同方案接种三剂非致病性流感嗜血杆菌-卡他莫拉菌(NTHi-Mcat)疫苗的安全性和免疫原性:一项 2 期、随机、观察者盲法研究。
Respir Res. 2022 May 4;23(1):114. doi: 10.1186/s12931-022-02019-4.
慢性阻塞性肺疾病急性加重期细菌感染:系统评价和荟萃分析。
Infection. 2020 Feb;48(1):19-35. doi: 10.1007/s15010-019-01350-1. Epub 2019 Sep 3.
4
Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial.成人 COPD 患者中无法分型流感嗜血杆菌蛋白疫苗:一项 2 期临床试验。
Vaccine. 2019 Sep 24;37(41):6102-6111. doi: 10.1016/j.vaccine.2019.07.100. Epub 2019 Aug 22.
5
Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine.无乳链球菌-卡他莫拉菌疫苗的安全性和免疫原性。
Vaccine. 2019 May 21;37(23):3113-3122. doi: 10.1016/j.vaccine.2019.04.041. Epub 2019 Apr 24.
6
Drivers of year-to-year variation in exacerbation frequency of COPD: analysis of the AERIS cohort.慢性阻塞性肺疾病急性加重频率逐年变化的驱动因素:AERIS队列分析
ERJ Open Res. 2019 Feb 25;5(1). doi: 10.1183/23120541.00248-2018. eCollection 2019 Feb.
7
Patients with Chronic Obstructive Pulmonary Disease harbour a variation of Haemophilus species.慢性阻塞性肺疾病患者携带流感嗜血杆菌变异体。
Sci Rep. 2018 Oct 3;8(1):14734. doi: 10.1038/s41598-018-32973-3.
8
Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations.AERIS 研究中的肺部微生物组纵向分析表明细菌和嗜酸性 COPD 加重具有可重复性。
Thorax. 2018 May;73(5):422-430. doi: 10.1136/thoraxjnl-2017-210408. Epub 2018 Jan 31.
9
Molecular viability testing of viable but non-culturable bacteria induced by antibiotic exposure.抗生素暴露诱导的活但非可培养细菌的分子活力测试。
Microb Biotechnol. 2018 Nov;11(6):1008-1016. doi: 10.1111/1751-7915.13039. Epub 2017 Dec 15.
10
Insights on persistent airway infection by non-typeable Haemophilus influenzae in chronic obstructive pulmonary disease.关于非典型流感嗜血杆菌在慢性阻塞性肺疾病中持续气道感染的见解
Pathog Dis. 2017 Jun 1;75(4). doi: 10.1093/femspd/ftx042.